Supplementary figures.docx (753.69 kB)

Supplementary figures: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.docx

figure

posted on 2021-08-31, 10:18 authored by Stacey M. Stein, Jeremy Snider, Siraj M. Ali, Rebecca A. Miksad, Brian M. Alexander, Emily Castellanos, Alexa B. Schrock, Russell Madison, Akshay Swaminathan, Jeffrey M. Venstrom, Margaret McCusker

Supplemental figure 1: Cohort attrition

Supplemental Figure 2: TTD and OS by IHC status for HER2 ISH+ patients with IHC results (n = 38)

Supplemental figure 3: TTD and OS by KRAS status

History

Usage metrics

Keywords

Gastrointestinal/Esophageal cancer Trastuzumab Real-world evidence HER2 next generation sequencing comprehensive genomic profiling immunohistochemistry in situ hybridization molecular alteration Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0